Results for mielosupresivni translation from Slovenian to English

grastofil za izplavljanje pbpc po mielosupresivni kemoterapiji: grastofil je treba dati s subkutano injekcijo.
grastofil for pbpc mobilisation after myelosuppressive chemotherapy: grastofil should be given by subcutaneous injection.

filgrastim za mobilizacijo pbpc po mielosupresivni kemoterapiji: filgrastim je treba dajati v obliki subkutane injekcije.
filgrastim for pbpc mobilisation after myelosuppressive chemotherapy: filgrastim should be given by subcutaneous injection.

priporočen odmerek filgrastima za zbiranje matičnih celic iz periferne krvi po mielosupresivni kemoterapiji je 0, 5 x 106i. e.
the recommended dose of filgrastim for pbpc mobilisation after myelosuppressive chemotherapy is 0.5 miu (5 μ g)/ kg/ day given daily by subcutaneous injection from the first day after completion of chemotherapy until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.

to vodi do zmanjšanja števila krožečih rdečih in belih krvničk ter krvnih ploščic (mielosupresivni učinek).
these effects lead to a reduction of circulating red, white and coagulation blood cells (myelosuppressive effect).

izkazalo se je, da s filgrastimom zbrane matične celice v periferni krvi zmanjšujejo resnost in trajanje trombocitopenije po mielosupresivni ali mieloablativni kemoterapiji.
the use of filgrastim-mobilised pbpcs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.

ugotovljeno je bilo, da uporaba matičnih celic, izplavljenih s filgrastimom, zmanjša izrazitost in trajanje trombocitopenije po mielosupresivni ali mieloablacijski kemoterapiji.
the use of filgrastim-mobilised pbpcs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.

po enem samem subkutanem odmerku pegfilgrastima se najvišja serumska koncentracija pegfilgrastima pojavi 16 do 120 ur po odmerku, serumske koncentracije pegfilgrastima se vzdržujejo v obdobju nevtropenije po mielosupresivni kemoterapiji.
after a single subcutaneous dose of pegfilgrastim, the peak serum concentration of pegfilgrastim occurs at 16 to 120 hours after dosing and serum concentrations of pegfilgrastim are maintained during the period of neutropenia after myelosuppressive chemotherapy.

nekateri ljudje z dedno oslabljenim delovanjem encima tpmt so zelo občutljivi na mielosupresivni učinek 6-merkaptopurina in nagnjeni k hitremu razvoju depresije kostnega mozga po začetku zdravljenja s 6-merkaptopurinom.
there are individuals with an inherited deficiency of the tpmt enzyme activity who are very sensitive to the myelosuppresive effect of 6–mercaptopurine and prone to developing rapid bone marrow depression following the initiation of treatment with 6–mercaptopurine.

v dveh randomiziranih, dvojno slepih ključnih študijah pri bolnikih z visoko tveganim rakom na dojki v ii. do iv. stadiju na mielosupresivni kemoterapiji z doksorubicinom in docetakselom je uporaba pegfilgrastima v obliki enega samega odmerka na cikel skrajšala trajanje nevtropenije in incidenco febrilne nevtropenije, podobno kot so opazili pri vsakodnevni uporabi filgrastima (mediana števila dnevnih aplikacij je bila 11).
in two randomised, double-blind, pivotal studies in patients with high risk stage ii-iv breast cancer undergoing myelosuppressive chemotherapy consisting of doxorubicin and docetaxel, use of pegfilgrastim, as a single once per cycle dose, reduced the duration of neutropenia and the incidence of febrile neutropenia similarly to that observed with daily administrations of filgrastim (a median of 11 daily administrations).